| pubmed-article:18424761 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18424761 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:18424761 | lifeskim:mentions | umls-concept:C0205252 | lld:lifeskim |
| pubmed-article:18424761 | lifeskim:mentions | umls-concept:C0023434 | lld:lifeskim |
| pubmed-article:18424761 | lifeskim:mentions | umls-concept:C1325804 | lld:lifeskim |
| pubmed-article:18424761 | lifeskim:mentions | umls-concept:C1155229 | lld:lifeskim |
| pubmed-article:18424761 | lifeskim:mentions | umls-concept:C0237881 | lld:lifeskim |
| pubmed-article:18424761 | lifeskim:mentions | umls-concept:C0220901 | lld:lifeskim |
| pubmed-article:18424761 | lifeskim:mentions | umls-concept:C0750502 | lld:lifeskim |
| pubmed-article:18424761 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:18424761 | pubmed:dateCreated | 2008-4-21 | lld:pubmed |
| pubmed-article:18424761 | pubmed:abstractText | Chronic lymphocytic leukemia (CLL) is characterized by a highly variable clinical course. The role of an autologous tumor-specific immune control contributing to the variable length of survival in CLL is poorly understood. We investigated whether humoral immunity specific for the CLL-associated Ag oncofetal Ag/immature laminin receptor (OFA/iLR) has a prognostic value in CLL. Among sera of 67 untreated patients with CLL, 23 (34.3%) had detectable OFA/iLR Abs that were reactive for at least one specific OFA/iLR epitope. Patients with humoral responses compared with patients with nonreactive sera had a longer progression-free survival (p = 0.029). IgG subclass analyses showed a predominant IgG1 and IgG3 response. OFA/iLR Abs were capable of recognizing and selectively killing OFA/iLR-expressing CLL cells in complement-mediated and Ab-dependent cellular cytotoxicity assays. In the analysis of 11 CLL patients after allogeneic hematopoietic stem cell transplantation, 8 showed high values for OFA/iLR Abs that specifically recognized the extracellular domain of the protein, suggesting a potential role of anti-OFA/iLR-directed immune responses to the graft-vs-leukemia effect in CLL. Our data suggest that spontaneous tumor-specific humoral immune responses against OFA/iLR exist in a significant proportion of CLL patients and that superior progression-free survival in those patients could reflect autologous immune control. | lld:pubmed |
| pubmed-article:18424761 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18424761 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18424761 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:18424761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18424761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18424761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18424761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18424761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18424761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18424761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18424761 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18424761 | pubmed:month | May | lld:pubmed |
| pubmed-article:18424761 | pubmed:issn | 0022-1767 | lld:pubmed |
| pubmed-article:18424761 | pubmed:author | pubmed-author:RohrerJamesJ | lld:pubmed |
| pubmed-article:18424761 | pubmed:author | pubmed-author:SchmitzNorber... | lld:pubmed |
| pubmed-article:18424761 | pubmed:author | pubmed-author:KabelitzDiete... | lld:pubmed |
| pubmed-article:18424761 | pubmed:author | pubmed-author:TiemannMarkus... | lld:pubmed |
| pubmed-article:18424761 | pubmed:author | pubmed-author:ZeisMatthiasM | lld:pubmed |
| pubmed-article:18424761 | pubmed:author | pubmed-author:SteinmannJörg... | lld:pubmed |
| pubmed-article:18424761 | pubmed:author | pubmed-author:HeidornKlausK | lld:pubmed |
| pubmed-article:18424761 | pubmed:author | pubmed-author:SiegelSandraS | lld:pubmed |
| pubmed-article:18424761 | pubmed:author | pubmed-author:CogginJosephJ... | lld:pubmed |
| pubmed-article:18424761 | pubmed:author | pubmed-author:BarsoumAdelA | lld:pubmed |
| pubmed-article:18424761 | pubmed:author | pubmed-author:KloessMaritaM | lld:pubmed |
| pubmed-article:18424761 | pubmed:author | pubmed-author:FriedrichsBir... | lld:pubmed |
| pubmed-article:18424761 | pubmed:author | pubmed-author:SchulteChrist... | lld:pubmed |
| pubmed-article:18424761 | pubmed:author | pubmed-author:JakobIljaI | lld:pubmed |
| pubmed-article:18424761 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18424761 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:18424761 | pubmed:volume | 180 | lld:pubmed |
| pubmed-article:18424761 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18424761 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18424761 | pubmed:pagination | 6374-84 | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:meshHeading | pubmed-meshheading:18424761... | lld:pubmed |
| pubmed-article:18424761 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18424761 | pubmed:articleTitle | Humoral immune responses against the immature laminin receptor protein show prognostic significance in patients with chronic lymphocytic leukemia. | lld:pubmed |
| pubmed-article:18424761 | pubmed:affiliation | Department of Hematology and Stem Cell Transplantation, Asklepios Hospital St. Georg, Lohmühlenstrasse 5, Hamburg, Germany. | lld:pubmed |
| pubmed-article:18424761 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18424761 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
